Table 1.
Demographic and clinical characteristics between control group, PMR and EORAneg at baseline
| Variable | Control N=18 |
PMR N=20 |
EORAneg N=28 |
p |
|---|---|---|---|---|
| Female, n (%) | 11(61) | 17(85) | 12(43) *** | 0.01 |
| Age, years | 75.39±6.04 | 76.40±4.99 | 76.75±6.99 | 0.76 |
| BMI, kg/m2 | 28.84±5.56 | 27.27±4.32 | 28.82±4.76 | 0.50 |
| DM, n (%) | 3(16) * | 5(25) | 15(54) *** | 0.02 |
| HBP, n (%) | 11(61) | 17(85) | 20(71) | 0.25 |
| DL, n (%) | 9(50) | 12(60) | 19(67) | 0.48 |
| CRP mg/dL | 4.10±6.78* | 31.56±28.27 | 41.57±52.14 | 0.02 |
| ESR mm/h | 17.93±17.03* | 57.80±21.50** | 52.54±27.20 | <0.001 |
| TNF (pg/mL) | 15.05±19.86 | 13.60±6.12 | 13.86±6.68 | 0.93 |
| IL-6 (pg/mL) | 1.04±1.43* | 11.25±23.92 | 19.93±29.45 | 0.03 |
| Fatigue, n (%) | 14 (70) | 20 (71.4) | 0.92 | |
| Weight loss, n (%) | 8 (40) | 10 (36) | 0.76 | |
| Anorexia, n (%) | 7 (35) | 14 (50) | 0.30 | |
| Stiffness, n (%) | 19 (95) | 27 (96) | 0.81 | |
| Shoulder pain, n (%) | 20 (100) | 21 (75) | 0.02 | |
| Pelvis pain, n (%) | 18 (90) | 13 (64) | <0.001 | |
| Tender Joints | 2.70 ± 0.98 | 9.11 ± 5.83 | <0.001 | |
| Swollen Joints | 0.25 ± 0.64 | 11.46 ± 5.89 | <0.001 | |
| Pain | 81.25 ± 17.46 | 73.04 ± 17.81 | 0.12 | |
| HAQ | 1.50 ± 0.57 | 1.77 ± 0.80 | 0.18 | |
| DAS-CRP | 5.64±0.99 | |||
| DAS-ESR | 6.21±1.00 | |||
| NSAIDs mg | 520.00 ± 44.72 | 450.00 ± 216.35 | 0.35 | |
| NSAIDs, n (%) | 5 (25) | 11 (39.3) | 0.36 |
Continuous variables expressed in mean ± standard deviation; Categorical variables expressed as percentages. Quantitative variables between three groups were analyzed using ANOVA (Scheffe post-hoc). Student t-test was used to compare quantitative variables between variables present only in EORAneg and PMR. Chi-square analysis was used to determine the significance between groups for qualitative variables. Note. BMI: Body mass index; DM: Diabetes mellitus; HBP: high blood pressure; DL: Dyslipidemia; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; TNF: Tumor necrosis factor; IL-6: Interleukin 6.
p<0.05 Control vs EORAneg
p<0.05 Control vs PMR
p<0.05 EORAneg vs PMR